-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The significance of external beam radiotherapy in the treatment of locally advanced non-undifferentiated thyroid cancer is still controversial
.
This prospective study evaluated the efficacy and tolerability of intensity-modulated radiotherapy (IMRT) with or without concurrent chemotherapy for patients with locally advanced thyroid cancer
*Intensity modulated radiation therapy (IMRT) refers to intensity modulated radiation therapy, which is a type of three-dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements, referred to as intensity modulated radiation therapy
.
.
Representative intensity-modulated radiotherapy treatment plan
Representative intensity-modulated radiotherapy treatment planThis is a non-randomized phase 2 trial that recruited patients with grossly residual or unresectable non-undifferentiated thyroid cancer to receive IMRT± concurrent doxorubicin chemotherapy
.
The primary endpoint is 2-year local progression-free survival (PFS); secondary endpoints include overall survival (OS), safety, patient-reported prognosis, and functional prognosis
Response of patients in the two treatment groups to treatment
Response of patients in the two treatment groups to treatmentA total of 27 patients were recruited: 12 (44.
4%) were unresectable lesions, and 15 (55.
6%) were gross residual lesions
.
The median follow-up was 45.
The median follow-up was 45.
Incidence of toxic events
Incidence of toxic eventsThe incidence of acute and late toxicity events of grade 3 and above was 33.
4%
.
Within 12 months after treatment, there was no significant functional difference between the two groups
In the post-mortem analysis, the 2-year local failure rate in the concurrent chemotherapy and intensity-modulated radiotherapy (CC-IMRT) group was significantly reduced (0% vs 50%; p=0.
001) , accompanied by acute dermatitis, mucositis and grade 2 and above The incidence of dysphagia increased significantly, and there were no significant differences in long-term toxic events, functions, or patient-reported life treatments between the two treatment groups
.
001) The 2-year local failure rate in the concurrent chemotherapy and intensity-modulated radiotherapy (CC-IMRT) group was significantly lower Decrease (0% vs 50%; p=0.
001)
In summary, given that CC-IMRT achieves excellent local control rates and acceptable toxicity characteristics, as confirmed by functional assessment and patient-reported prognosis, for patients with locally advanced non-undifferentiated thyroid cancer, CC-IMRT is integrated The benefit may be better than IMRT treatment alone
.
It is better than IMRT alone
.
In view of the excellent local control rate and acceptable toxicity characteristics of CC-IMRT, as confirmed by functional assessment and patient-reported prognosis, the comprehensive benefits of CC-IMRT may be possible for patients with locally advanced non-undifferentiated thyroid cancer.
Original source
Romesser Paul B, Sherman Eric J, Whiting Karissa et al.
Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial in this message
